Are your patients taking or asking you about the new GLP-1RA weight loss medications (Semaglutide, Ozempic, Wegovy, Tirzepatide, Mounjaro, Zepbound)?

This webinar with obesity medicine physician Jonathan Bonnet, MD, MPH, will go through all the ins and outs of what these medications are, how they work, how to safely prescribe and deprescribe them, their risks and benefits, their common side effects, and how to determine if a patient is a good candidate for them or not.

Click play above to watch.

Dr. Bonnet is quadruple board certified in family, sports, obesity, and lifestyle medicine and is a clinical associate professor (affiliated) at Stanford University School of Medicine. He is the program director of medical weight loss at the Palo Alto VA's weight management center and was the top prescriber of Semaglutide the previous year at the Palo Alto VA (though receives no funding or support from Nova Nordisk or Eli Lilly). He completed his undergraduate and medical school degrees at Ohio State University, family medicine residency at Duke University, and sports medicine fellowship at the University of Florida. He also holds a master’s degree in public health from Harvard.